fetal heart
Recently Published Documents





2022 ◽  
Vol 9 (3) ◽  
pp. 0-0

Cardiotocography (CTG) is the widely used cost-effective, non-invasive technique to monitor the fetal heart and mother’s uterine contraction pressure to assess the wellbeing of the fetus. The most important parameters of fetal heart is the baseline upon which the other parameters viz. acceleration, deceleration and variability depend. Accurate classification of the baseline into either normal, bradycardia or tachycardia is thus important to assess the fetal-health. Since visual estimation has its limitations, the authors use various Machine Learning Algorithms to classify the baseline. 110 CTG traces from CTU-UHB dataset, were divided into three subsets using stratified sampling to ensure that the sample is the accurate depiction of the population. The results were analyzed using various statistical methods and compared with the visual estimation by three obstetricians. FURIA provided greatest accuracy of 98.11%. From the analysis of Bland-Altman Plot FURIA was also found to have best agreement with physicians’ estimation.

eLife ◽  
2022 ◽  
Vol 11 ◽  
Lucas C Pantaleao ◽  
Isabella Inzani ◽  
Samuel Furse ◽  
Elena Loche ◽  
Antonia Hufnagel ◽  

Maternal obesity during pregnancy has immediate and long-term detrimental effects on the offspring heart. In this study, we characterized the cardiac and circulatory lipid profiles in late gestation E18.5 fetuses of diet-induced obese pregnant mice and established the changes in lipid abundance and fetal cardiac transcriptomics. We used untargeted and targeted lipidomics and transcriptomics to define changes in the serum and cardiac lipid composition and fatty acid metabolism in male and female fetuses. From these analyses we observed: (1) maternal obesity affects the maternal and fetal serum lipidome distinctly; (2) female fetal heart lipidomes are more sensitive to maternal obesity than males; (3) changes in lipid supply might contribute to early expression of lipolytic genes in mouse hearts exposed to maternal obesity. These results highlight the existence of sexually dimorphic responses of the fetal heart to the same in utero obesogenic environment and identify lipids species that might mediate programming of cardiovascular health.

Sherzana Sunderji ◽  
Shabnam Peyvandi ◽  
Edgar Jaeggi ◽  
Anita Szwast ◽  
Greg Ryan ◽  

Sushma Tumkur Venugopal ◽  
Sriraam Natarajan ◽  
Megha P. Arakeri ◽  
Suresh Seshadri

Fetal Echocardiography is used for monitoring the fetal heart and for detection of Congenital Heart Disease (CHD). It is well known that fetal cardiac four chamber view has been widely used for preliminary examination for the detection of CHD. The end diastole frame is generally used for the analysis of the fetal cardiac chambers which is manually picked by the clinician during examination/screening. This method is subjected to intra and inter observer errors and also time consuming. The proposed study aims to automate this process by determining the frame, referred to as the Master frame from the cine loop sequences that can be used for the analysis of the fetal heart chambers instead of the clinically chosen diastole frame. The proposed framework determines the correlation between the reference (first) frame with the successive frames to identify one cardiac cycle. Then the Master frame is formed by superimposing all the frames belonging to one cardiac cycle. The master frame is then compared with the clinically chosen diastole frame in terms of fidelity metrics such as Dice coefficient, Hausdorff distance, mean square error and structural similarity index. The average value of the fidelity metrics considering the dataset used for this study 0.73 for Dice, 13.94 for Hausdorff distance, 0.99 for Structural Similarity Index and 0.035 for mean square error confirms the suitability of the proposed master frame extraction thereby avoiding manual intervention by the clinician. .

Wadi Mawad ◽  
Lisa Hornberger ◽  
Bettina Cuneo ◽  
Marie‐Josée Raboisson ◽  
Anita J. Moon‐Grady ◽  

Background Transplacental fetal treatment of immune‐mediated fetal heart disease, including third‐degree atrioventricular block (AVB III) and endocardial fibroelastosis, is controversial. Methods and Results To study the impact of routine transplacental fetal treatment, we reviewed 130 consecutive cases, including 108 with AVB III and 22 with other diagnoses (first‐degree/second‐degree atrioventricular block [n=10]; isolated endocardial fibroelastosis [n=9]; atrial bradycardia [n=3]). Dexamethasone was started at a median of 22.4 gestational weeks. Additional treatment for AVB III included the use of a β‐agonist (n=47) and intravenous immune globulin (n=34). Fetal, neonatal, and 1‐year survival rates with AVB III were 95%, 93%, and 89%, respectively. Variables present at diagnosis that were associated with perinatal death included an atrial rate <90 beats per minute (odds ratio [OR], 258.4; 95% CI, 11.5–5798.9; P <0.001), endocardial fibroelastosis (OR, 28.9; 95% CI, 1.6–521.7; P <0.001), fetal hydrops (OR, 25.5; 95% CI, 4.4–145.3; P <0.001), ventricular dysfunction (OR, 7.6; 95% CI, 1.5–39.4; P =0.03), and a ventricular rate <45 beats per minute (OR, 12.9; 95% CI, 1.75–95.8; P =0.034). At a median follow‐up of 5.9 years, 85 of 100 neonatal survivors were paced, and 1 required a heart transplant for dilated cardiomyopathy. Cotreatment with intravenous immune globulin was used in 16 of 22 fetuses with diagnoses other than AVB III. Neonatal and 1‐year survival rates of this cohort were 100% and 95%, respectively. At a median age of 3.1 years, 5 of 21 children were paced, and all had normal ventricular function. Conclusions Our findings reveal a low risk of perinatal mortality and postnatal cardiomyopathy in fetuses that received transplacental dexamethasone±other treatment from the time of a new diagnosis of immune‐mediated heart disease.

2022 ◽  
Rebecca Wilson ◽  
Victor Yuan ◽  
Jennifer Alexander Courtney ◽  
Alyssa Tipler ◽  
James Cnota ◽  

Congenital heart disease (CHD) is often associated with fetal growth abnormalities. During the first trimester of pregnancy, the heart and placenta develop concurrently, and share key developmental pathways. Hence, it is hypothesized that defective morphogenesis of either organ is synergistically linked. However, many studies determined to understand the mechanisms behind CHD overlook the contribution of the placenta. In this study, we aimed to identify commonly expressed genes between first trimester heart and placenta cells using two publicly available single cell sequencing databases. Using a systematic computational approach, we identified 328 commonly expressed genes between heart and placenta endothelial cells and enrichment in pathways including Vasculature Development (GO:0001944, FDR 2.90E-30), and Angiogenesis (GO:0001525, FDR 1.18E-27). We also found, in comparison with fetal heart endothelial cells, 197 commonly expressed genes with placenta extravillous trophoblasts, 128 with cytotrophoblasts and 80 with syncytiotrophoblasts, and included genes such as FLT1, GATA2, ENG and CDH5. Finally, comparison of first trimester cardiomyocytes and placenta cytotrophoblasts revealed 53 commonly expressed genes and enrichment in biological processes integral to cellular function including Cellular Respiration (GO:0045333; FDR 5.05E-08), Ion Transport (GO:0006811; FDR 2.08E-02), and Oxidation-Reduction Process (GO:0055114; FDR 1.58E-07). Overall, our results identify specific genes and cellular pathways common between first trimester fetal heart and placenta cells which if disrupted may concurrently contribute to the developmental perturbations resulting in CHD.

2022 ◽  
Vol 226 (1) ◽  
pp. S656-S657
Quentin Noirhomme ◽  
Elisa Rossetti ◽  
Hanne Marien ◽  
Daimy Roebroek ◽  
Michiel Rooijakkers ◽  

2022 ◽  
Vol 226 (1) ◽  
pp. S676
Delphine Le Hesran ◽  
Louise Ghesquière ◽  
Geoffroy Chevalier ◽  
Jean-David Pékar ◽  
Dyuti Sharma ◽  

Sign in / Sign up

Export Citation Format

Share Document